Unity Biotechnology Price Target & Analyst Ratings (NASDAQ:UBX)

$7.08
+0.11 (+1.58 %)
(As of 09/20/2019 02:57 PM ET)
Today's Range
$7.02
Now: $7.08
$7.27
50-Day Range
$5.70
MA: $6.62
$7.96
52-Week Range
$5.61
Now: $7.08
$18.32
Volume9,177 shs
Average Volume233,866 shs
Market Capitalization$305.86 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.2

Analyst Ratings

Unity Biotechnology (NASDAQ:UBX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Unity Biotechnology in the last 12 months. Their average twelve-month price target is $17.50, suggesting that the stock has a possible upside of 147.18%. The high price target for UBX is $21.00 and the low price target for UBX is $14.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.002.80
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $17.50$22.6667$26.00$25.40
Price Target Upside: 147.18% upside191.72% upside186.34% upside179.74% upside

Unity Biotechnology (NASDAQ:UBX) Consensus Price Target History

Unity Biotechnology (NASDAQ:UBX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/15/2019Morgan StanleySet Price TargetBuy$14.00Medium
3/6/2019Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$21.00High
3/6/2019MizuhoReiterated RatingBuyHigh
5/29/2018CitigroupInitiated CoverageBuy$32.00High
5/29/2018Goldman Sachs GroupInitiated CoverageNeutral$17.00High
(Data available from 9/20/2017 forward)
This page was last updated on 9/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel